Join
Live feed
·
PRReleasevia Quantisnow
Ovid Therapeutics Inc. logo

Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results

ByQuantisnow·Wall Street's wire, on your screen.

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track OVID (Ovid Therapeutics Inc.) and more on Quantisnow.